PCSK9 and acute myocardial infarction: In pre-PCI statin and hydration therapy, the results showed that the prevalence of CI-AKI in patients with acute myocardial infarction who received evolocumab was 6.7%, which was significantly less than the rate of 20.0% in the group that did not receive the PCSK9 inhibitor.